Efficacy and safety of ophthalmic epinastine evaluated using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis

被引：0

作者：

Schiffman, RM

Abelson, MB

Crampton, HJ

Slugg, AP

Michaelson, C

Bradford, RR

Kim, B

Lue, JC

Whitcup, SM

机构：

[1] Allergan Pharmaceut Inc, Irvine, CA USA

[2] Schepens Eye Res Inst, Boston, MA USA

[3] Ophthalm Res Associates, N Andover, MA USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2002年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

107

引用

页码：U17 / U17

页数：1

共 50 条

[21] EFFICACY AND SAFETY OF NEDOCROMIL SODIUM OPHTHALMIC SOLUTION IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS
BLUMENTHAL, M
CASALE, T
DOCKHORN, R
JARMOSZUK, I
KAISER, H
SMITH, R
ZEITZ, HJ
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1992, 113 (01) : 56 - 63
[22] Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis
Berdy, Gregg J.
Oliff, Heather S.
EXPERT REVIEW OF OPHTHALMOLOGY, 2010, 5 (05) : 595 - 602
[23] Clinical efficacy and preference of Visine-A and Patanol in preventing the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge model
Frisch, SI
Druce, H
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
[24] The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis
Torkildsen, Gail
Shedden, Arthur
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 623 - 631
[25] Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge
Mah, Francis S.
Rosenwasser, Lanny J.
Townsend, William D.
Greiner, Jack V.
Bensch, George
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1445 - 1452
[26] Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Williams, J. I.
McLaurin, E. B.
Kurata, F. K.
Abelson, M. B.
Gow, J. A.
McNamara, T. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB257 - AB257
[27] Comparing Efficacy and Safety of Olopatadine and Emedastine in Patients with Allergic Conjunctivitis
Cao, Shiyan
Cao, Shining
Chen, Aiwei
Yang, Lanlan
Chen, Yuan
INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2019, 15 (03) : 327 - 335
[28] Safety and efficacy of nedocromil sodium ophthalmic solution 2% BID in patients with ocular itch associated with allergic conjunctivitis.
Tauber, J
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (04) : S910 - S910
[29] Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model
Abelson, MB
Greiner, JV
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) : 1953 - 1958
[30] Phase III study of new high-dose olopatadine 0.77% formulation in patients with allergic conjunctivitis using the conjunctival allergen challenge model
Torkildsen, G.
ALLERGY, 2013, 68 : 650 - 651

← 1 2 3 4 5 →